#USA #Denver #AusperBio #AHB-137 #AASLD

AusperBio to Present Groundbreaking AHB-137 Treatment Data at AASLD 2026

In a significant advancement in the fight against chronic hepatitis B, AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd., both working under the umbrella of AusperBio, will present compelling long-term follow-up data on AHB-137 treatment during two late-breaking oral presentations at The Liver Meeting® 2026. Taking place from November 5-9 in Denver, Colorado, this annual meeting organized by the American Association for the Study of Liver Diseases (AASLD) will see the unveiling of critical findings from the AB-10-8004 study (NCT07146100).

The presentations will focus on two distinct groups involved in the clinical trials of AHB-137: first, those experienced with nucleos(t)ide analogue (NA) treatment, and second, treatment-naïve individuals who received monotherapy with AHB-137, an innovative investigative drug targeting chronic hepatitis B.

Insights from AusperBio Leadership

Chris Yang, Co-founder and Chief Scientific Officer of AusperBio, expressed their gratitude and excitement over being selected for these late-breaking presentations. He remarked, "We are honored that two abstracts from the AB-10-8004 study have been selected for late-breaking oral presentations at The Liver Meeting®. We look forward to sharing these long-term follow-up data with the hepatology community as we continue to advance AHB-137 toward our goal of a functional cure for chronic hepatitis B."

Presentation Details

1. Durability of AHB-137 Treatment in NA Treated Participants

• - Publication Number: 5001
• - Abstract Title: Durability of AHB-137 up to 9 Month Post End-of-Studies in Nucleos(t)ide Analogue Treated Participants with Chronic Hepatitis B
• - Session: Late Breaking Abstract Parallel Session
• - Date and Time: November 8, 2026, from 2:00 PM to 2:15 PM MT
• - Presenter: Dr. Jinlin Hou, Southern Medical University, Guangdong, China

2. Long-Term Results for Treatment-Naïve Participants

• - Publication Number: 5010
• - Abstract Title: Durability of Functional Cure to AHB-137 Monotherapy in Treatment-Naïve Participants with Chronic Hepatitis B Long-Term Follow-Up Results of the AB-10-8004 Study
• - Session: Late Breaking Abstract Parallel Session 2
• - Date and Time: November 8, 2026, from 6:00 PM to 6:15 PM MT
• - Presenter: Dr. Junqi Niu, The First Hospital of Jilin University, Changchun, China

The late-breaking abstracts will be accessible on the AASLD website starting at 8:00 AM MT on November 5, 2026, coinciding with the initial day of the conference. AusperBio has indicated plans to distribute a subsequent press release that will outline further details after the presentations.

About AHB-137

AHB-137 is AusperBio’s premier investigational unconjugated antisense oligonucleotide (ASO) therapy targeting chronic hepatitis B, developed through the innovative Med-Oligo™ ASO platform. This therapy aims to suppress hepatitis B surface antigen (HBsAg) production, inhibit viral DNA replication, and stimulate immune reactivation, with the intent to achieve a functional cure for chronic hepatitis B.

The therapy has shown promising clinical outcomes and is currently undergoing evaluation in a Phase 3 trial in China, in addition to previous global Phase 1 and multiple Phase 2 studies. AusperBio is actively pursuing a coordinated global development strategy to advance AHB-137 towards potential commercialization.

About AusperBio

AusperBio is a near-commercial biopharmaceutical firm dedicated to developing unique oligonucleotide therapeutics and specialized delivery technologies, with a primary focus on achieving a functional cure for chronic hepatitis B. The company’s innovative platform includes the proprietary Med-Oligo™ ASO and Au-HALO™ targeted delivery technologies, which bolster the development of therapies across multiple oligonucleotide modalities. With several clinical-stage programs and an expanding pipeline, AusperBio is committed to a backbone-based strategy for curing chronic hepatitis B while exploring additional diseases with high unmet medical needs.

For more information about AusperBio and its initiatives, visit www.ausperbio.com.

Forward-Looking Statements

This press release includes forward-looking statements, indicative of future expectations. Such statements involve risks and uncertainties that may materially impact actual results. AusperBio does not update or revise forward-looking statements except as legally required. Media inquiries can be directed to [media contact email]. For investor inquiries, please call 650-888-1756 or email [investor contact email].